Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more
Korean Drug Co. Ltd (014570) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.046x
Based on the latest financial reports, Korean Drug Co. Ltd (014570) has a cash flow conversion efficiency ratio of 0.046x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.72 Billion) by net assets (₩81.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Korean Drug Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Korean Drug Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Korean Drug Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korean Drug Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fodelia
HE:FODELIA
|
0.042x |
|
CHAR Technologies Ltd
PINK:CTRNF
|
-0.242x |
|
Hubei Geoway Investment Co Ltd
SHG:600462
|
0.893x |
|
Moonbae Steel
KO:008420
|
-0.026x |
|
Rand Mining Ltd
AU:RND
|
0.048x |
|
Libertas 7 SA
MC:LIB
|
-0.008x |
|
KCP Sugar and Industries Corporation Limited
NSE:KCPSUGIND
|
0.087x |
|
Tan Chong Motor Holdings Bhd
KLSE:4405
|
0.093x |
Annual Cash Flow Conversion Efficiency for Korean Drug Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Korean Drug Co. Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩78.11 Billion | ₩4.87 Billion | 0.062x | +340.45% |
| 2023-12-31 | ₩77.09 Billion | ₩-2.00 Billion | -0.026x | -137.14% |
| 2022-12-31 | ₩84.71 Billion | ₩5.91 Billion | 0.070x | -39.22% |
| 2021-12-31 | ₩76.69 Billion | ₩8.81 Billion | 0.115x | -34.00% |
| 2020-12-31 | ₩70.87 Billion | ₩12.33 Billion | 0.174x | +82.29% |
| 2019-12-31 | ₩65.05 Billion | ₩6.21 Billion | 0.095x | +3.56% |
| 2018-12-31 | ₩62.80 Billion | ₩5.79 Billion | 0.092x | +1074.16% |
| 2017-12-31 | ₩56.97 Billion | ₩447.20 Million | 0.008x | -89.37% |
| 2016-12-31 | ₩53.66 Billion | ₩3.96 Billion | 0.074x | -40.18% |
| 2015-12-31 | ₩49.68 Billion | ₩6.13 Billion | 0.123x | +34.95% |
| 2014-12-31 | ₩48.79 Billion | ₩4.46 Billion | 0.091x | -- |